SCHEMBL922938

SCHEMBL922938

CCCCn1ccnc(S(=O)(=O)Cc2cccc(F)c2)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 1/20 0.40
PDE1B Q01064 1/20 0.40
PDE1C Q14123 1/20 0.40
ALDH1A1 P00352 5/20 0.40
NPSR1 Q6W5P4 4/20 0.40
PKM P14618 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
CNR2 P34972 1/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
GRM2 Q14416 1/20 0.37
LMNA P02545 4/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
GRM4 Q14833 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ADORA2B P29275 2/20 0.35
ADORA1 P30542 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL923661 0.89 PDE1C (0.40) PDE1APDE1BPDE1CALDH1A1NPSR1
SCHEMBL922671 0.86 AKR1B1 (0.44) ALDH1A1TSHRCNR2KMT2ALMNA
SCHEMBL922528 0.84 MAOA (0.40) PDE1APDE1BPDE1CALDH1A1NPSR1
SCHEMBL922918 0.80 PDE4A (0.40) ALDH1A1NPSR1POLBKMT2AGRM2
SCHEMBL923795 0.80 AKR1B1 (0.39) ALDH1A1NPSR1TSHRCNR2POLB
SCHEMBL922907 0.80 BRD4 (0.46) ALDH1A1NPSR1GRM2LMNAMAOA
SCHEMBL923923 0.80 RECQL (0.41) ALDH1A1NPSR1TSHRMAPK1POLB
SCHEMBL923790 0.79 NPSR1 (0.39) ALDH1A1NPSR1PKMTSHRMAPK1
SCHEMBL924370 0.79 ALDH1A1 (0.45) ALDH1A1NPSR1TSHRGRM2LMNA
SCHEMBL924230 0.78 PLCG1 (0.42) ALDH1A1PKMPOLBKMT2AGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9102632-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2015-08-11 US claimed
EP-2250156-B1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2015-05-06 EP claimed
US-20140100235-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2014-04-10 US claimed
US-8637522-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2014-01-28 US claimed
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PAATENT GESELLSCHAFT (DE) 2011-01-20 US claimed
US-9102632-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2015-08-11 US disclosed
US-9102632-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2015-08-11 US disclosed
US-9102632-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2015-08-11 US disclosed
EP-2250156-B1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2015-05-06 EP disclosed
EP-2250156-B1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2015-05-06 EP disclosed
US-20140100235-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2014-04-10 US disclosed
US-8637522-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2014-01-28 US disclosed
US-8637522-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2014-01-28 US disclosed
US-8637522-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2014-01-28 US disclosed
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PAATENT GESELLSCHAFT (DE) 2011-01-20 US disclosed
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PAATENT GESELLSCHAFT (DE) 2011-01-20 US disclosed
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PAATENT GESELLSCHAFT (DE) 2011-01-20 US disclosed
EP-2250156-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES Merck Patent GmbH (DE) 2010-11-17 EP disclosed
WO-2009109259-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2009-09-11 WO disclosed
WO-2009109259-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140100235-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES GLP1R, GPR119, IAPP PDE1A 870/4885PDE1B 937/4885PDE1C 686/4885
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes GLP1R, IAPP, INSR PDE1A 978/4885PDE1B 1018/4885PDE1C 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.